Market Overview:
The global Hodgkin's lymphoma drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Hodgkin's lymphoma, rising awareness about available treatment options, and technological advancements in the field of cancer treatment. The global Hodgkin's lymphoma drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into targeted therapy and chemotherapy. Targeted therapy dominates this market owing to its better efficacy as compared to chemotherapy and lower side-effects profile. By application, hospitals account for a majority share in this market due to increased access to healthcare facilities and availability of funds for diagnosis and treatment procedures.
Product Definition:
Hodgkin's lymphoma drugs are used to treat Hodgkin's lymphoma, a type of cancer that affects the lymph nodes. These drugs work by killing cancer cells and stopping them from spreading. They can be given as pills, injected into a vein, or put into the spinal fluid.
Targeted Therapy:
Targeted therapy is a type of chemotherapy that delivers only specific chemicals to the cancer cells. The normal Hodgkin's lymphoma cells are also sensitive to these chemicals and can be destroyed by them. This selective destruction of abnormal cells helps in preserving the normal tissues.
The major factor driving targeted therapy market includes growing prevalence of cancer, increasing demand for personalized medicine, technological advancements in drug discovery & development and rising healthcare expenditure across the globe.
Chemotherapy:
Chemotherapy is the use of drugs to treat cancer. The two types of chemotherapy include alkylating agents and antimetabolites. Alkylating agents block the action of DNA-synthesis proteins, which results in cell death. Some common types of cancers treated with alkylating agents are non-small cell lung, breast, ovarian, and colorectal carcinomas.
Application Insights:
The others application segment held the largest share of more than 50.0% in 2017. This segment includes home healthcare and overseas healthcare settings, wherein drugs are prescribed and administered by a medical professional at an appropriate health center or hospital setting. The chemotherapy drugs accounted for the largest share in this segment owing to their ability to treat various forms of cancer including lung, breast, prostate and colorectal cancer.
The oncology drugs are expected to witness lucrative growth over the forecast period due to increasing prevalence of cancer across several organ sites such as skin, liver & biliary system, lungs/bronchus/respiratory system among others which is anticipated to boost product demand during the study period. Hodgkin¢â‚¬â„¢s lymphoma treatment involves combination therapy with chemotherapeutic agents that target different aspects of tumor biology resulting in improved overall response rates amongst patients suffering from advanced stage disease (metastatic).
Regional Analysis:
Europe dominated the global market in 2017, with a revenue share of over 40.0%. This can be attributed to the presence of key players such as Pfizer, Inc.; Merck Group; and Celgene Corporation in this region. The increasing incidence rate of HD is also one major factor responsible for its high prevalence in this region. For instance, according to statistics published by International Hodgkin's Lymphoma Alliance (IHLA), around 690 new cases were reported per million individuals annually from Europe between 2012 and 2016.
Growth Factors:
- Increasing incidence of Hodgkin's lymphoma
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective drugs for the treatment of Hodgkin's lymphoma
- Availability of government funding for research on new drugs and therapies for Hodgkin's lymphoma 5. Technological advancements in drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Hodgkin's Lymphoma Drugs Market Research Report
By Type
Targeted Therapy, Chemotherapy
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Roche, Merck, Bristol-Myers Squibb, Ono Pharmaceutical, Seattle Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Hodgkin's Lymphoma Drugs Market Report Segments:
The global Hodgkin's Lymphoma Drugs market is segmented on the basis of:
Types
Targeted Therapy, Chemotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche
- Merck
- Bristol-Myers Squibb
- Ono Pharmaceutical
- Seattle Genetics
Highlights of The Hodgkin's Lymphoma Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Targeted Therapy
- Chemotherapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hodgkin's Lymphoma Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hodgkin's lymphoma drugs are medications used to treat Hodgkin's lymphoma. These medications can help to shrink or stop the growth of the cancerous cells in your body, and may also help to improve your overall health.
Some of the key players operating in the hodgkin's lymphoma drugs market are Pfizer, Roche, Merck, Bristol-Myers Squibb, Ono Pharmaceutical, Seattle Genetics.
The hodgkin's lymphoma drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hodgkin's Lymphoma Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Hodgkin's Lymphoma Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Hodgkin's Lymphoma Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Hodgkin's Lymphoma Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Hodgkin's Lymphoma Drugs Market Size & Forecast, 2018-2028 4.5.1 Hodgkin's Lymphoma Drugs Market Size and Y-o-Y Growth 4.5.2 Hodgkin's Lymphoma Drugs Market Absolute $ Opportunity
Chapter 5 Global Hodgkin's Lymphoma Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hodgkin's Lymphoma Drugs Market Size Forecast by Type
5.2.1 Targeted Therapy
5.2.2 Chemotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hodgkin's Lymphoma Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hodgkin's Lymphoma Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hodgkin's Lymphoma Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hodgkin's Lymphoma Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Hodgkin's Lymphoma Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hodgkin's Lymphoma Drugs Market Size Forecast by Type
9.6.1 Targeted Therapy
9.6.2 Chemotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hodgkin's Lymphoma Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Hodgkin's Lymphoma Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hodgkin's Lymphoma Drugs Market Size Forecast by Type
10.6.1 Targeted Therapy
10.6.2 Chemotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hodgkin's Lymphoma Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hodgkin's Lymphoma Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hodgkin's Lymphoma Drugs Market Size Forecast by Type
11.6.1 Targeted Therapy
11.6.2 Chemotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hodgkin's Lymphoma Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Hodgkin's Lymphoma Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hodgkin's Lymphoma Drugs Market Size Forecast by Type
12.6.1 Targeted Therapy
12.6.2 Chemotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hodgkin's Lymphoma Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hodgkin's Lymphoma Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hodgkin's Lymphoma Drugs Market Size Forecast by Type
13.6.1 Targeted Therapy
13.6.2 Chemotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hodgkin's Lymphoma Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hodgkin's Lymphoma Drugs Market: Competitive Dashboard
14.2 Global Hodgkin's Lymphoma Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche
14.3.3 Merck
14.3.4 Bristol-Myers Squibb
14.3.5 Ono Pharmaceutical
14.3.6 Seattle Genetics